9 results about "Cerebral Malaria" patented technology

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The present invention belongs to the field of biomedical technology and specifically relates to the use of Akkermansia muciniphila in ameliorating and treating cerebral malaria caused by Plasmodium berghei. This study evaluated the efficacy of Akkermansia muciniphila alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating cerebral malaria in a mouse cerebral malaria model. The results suggest that the bacteria, whether used alone or in combination with other drugs, effectively improved mouse behavior, immune pathological damage to various organs, reduced parasitemia, and prolonged mouse survival, demonstrating its effectiveness in treating cerebral malaria in mice compared to using the drugs alone. Because Akkermansia muciniphila is a common probiotic in the human gut, the three drugs used in this study (dihydroartemisinin, rapamycin, and atorvastatin) are all currently in clinical use. Clinical translation for the treatment of human cerebral malaria caused by Plasmodium falciparum is highly feasible and can also shorten the conversion time. This study proposes for the first time the concept of bacterial-drug synergy, whereby probiotics can complement drug treatments, and provides a solution for the treatment of human cerebral malaria based on this concept.

The invention relates to application of a TNF-alpha antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention. In order to solve the problems that in the prior art, the drug resistance of chemical drugs is prominent, efficient vaccines are lacked, and mosquito-stage transmission blocking means are insufficient, TNF-alpha antibodies are injected into plasmodium infected hosts to block binding of host TNF-alpha and mosquito wengen receptors, so that IMD channels are activated, expression of anti-malarial effector factors TEP1 is promoted, and development of plasmodium in mosquito bodies is inhibited; meanwhile, the occurrence rate of host cerebral malaria is reduced, and the transmission blocking effect can be synergistically enhanced by combining with the anti-Pfs25 antibody. The method is accurate in targeting, specifically intervenes a TNF-alpha signal channel, and avoids non-specific damage; dual protection: synchronously blocking mosquito propagation and preventing severe malaria of a host; the blocking efficiency is remarkably improved by combining with the anti-Pfs25 antibody, and a new strategy is provided for malaria prevention and control.

The present invention belongs to the field of biomedical technology, and specifically relates to the application of Lactobacillus murinus driving GABA in the treatment of cerebral malaria in mice. The present invention found significantly enriched Lactobacillus murinus and confirmed that Lactobacillus murinus can produce GABA. Subsequently, in a mouse cerebral malaria model, the effects of Lactobacillus murinus and GABA on improving and treating mouse cerebral malaria were evaluated when Lactobacillus murinus and GABA were used alone or in conjunction with dihydroartemisinin. The results showed that whether used alone or in combination with dihydroartemisinin, the bacteria and its metabolite GABA can effectively improve mouse behavior, immune pathological damage to various organs, reduce parasitemia, and prolong mouse survival. Compared with the use of drugs alone, it can effectively treat mouse cerebral malaria. From the perspective of using probiotics to drive their metabolites to assist antimalarial drugs in the treatment of mouse cerebral malaria, the present invention provides a new solution for the treatment of severe malaria caused by falciparum malaria, especially human cerebral malaria.

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of DHA@ZIF-8 in the treatment of experimental cerebral malaria. In the disclosure, an experimental cerebral malaria model is first established. Subsequently, DHA@ZIF-8 is used for treatment in the model, and the therapeutic efficacy of the nanodrug against experimental cerebral malaria is evaluated using behavioral, pathological, and molecular biological techniques. In the disclosure, the use of ZIF-8 as a carrier achieves the effect of slowly releasing the drug, prolonging the duration of action of the drug in vivo, so as to more effectively kill Plasmodium. Compared with natural administration, this approach extends the duration of action of DHA.

The invention discloses a pharmaceutical composition of artesunate and Xingnaojing and application of the pharmaceutical composition, and relates to the technical field of pharmacy, the active ingredients of the pharmaceutical composition comprise artesunate and Xingnaojing injection, and the application of artesunate and Xingnaojing injection in preparation of drugs for treating cerebral malaria. According to the application disclosed by the invention, the artesunate and Xingnaojing have a remarkable treatment effect on experimental cerebral malaria mice, and a GPR68 / cAMP / EPAC1 signal channel is activated, so that a blood brain barrier is protected, and brain tissue damage is relieved. The research provides a new drug combination strategy for clinical treatment of cerebral malaria, and lays a theoretical foundation for deep understanding of the action mechanism of cerebral malaria.

The invention discloses a pharmaceutical composition of artesunate combined with Xuebijing and application of the pharmaceutical composition, and relates to the technical field of pharmacy, effective components of the pharmaceutical composition comprise artesunate and Xuebijing injection, and application of the artesunate and Xuebijing injection in preparation of drugs for treating cerebral malaria. According to the application disclosed by the invention, the artesunate combined with Xuebijing has a remarkable treatment effect on experimental cerebral malaria mice, and the expression of NO is improved by activating a VEGF / Akt / eNOS signal channel, so that liver, spleen and brain tissues are protected, the immune function is recovered, and the survival rate is further improved. The research provides a new drug combination strategy for clinical treatment of cerebral malaria, and lays a theoretical foundation for deep understanding of the action mechanism of cerebral malaria.

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of Akkermansia muciniphila (AKK) in the amelioration and treatment of cerebral malaria caused by Plasmodium berghei. The disclosure aims to evaluate the efficacy of AKK alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating experimental cerebral malaria in an experimental cerebral malaria model. The results indicate that AKK, whether used alone or in combination with drugs, can effectively ameliorate behavioral deficits and immunopathological damage of each organ, lower parasitemia levels, and prolong survival period of mice. Compared with the use of drug alone, the combination therapy can effectively treat the experimental cerebral malaria. The disclosure is the first to propose the concept of bacterial-drug synergy concept, and provides a solution to the treatment of human cerebral malaria on the basis of the concept.